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HEMOSTATIC FUNCTION 
OF ASPIRIN-TREATED 
PLATELETS VULNERABLE 
TO CARDIOPULMONARY 
BYPASS 
Altered shear-induced 
pathway 
The impaired hemostasis of aspirin-treated patients is an annoying prob- 
lem during and after cardiopulmonary bypass. The hemostatic function of 
platelets comprises two mechanisms: the shear-induced and the cyclooxy- 
genase pathways. Because the latter is inhibited in aspirin-treated patients, 
the hemostatic function depends mainly on the former pathway. To 
investigate the effect of cardiopulmonary bypass on the shear-induced 
pathway, a double-blind study of preoperative aspirin treatment (325 mg) 
and placebo was conducted in 40 patients undergoing coronary artery 
bypass grafting. Postoperative blood loss was higher in the aspirin-treated 
patients than in the placebo-treated patients (p < 0.05). The shear-induced 
hemostasis was monitored by the in vitro bleeding test (Thrombostat), 
which mimics bleeding through an injured arteriole. The shear-induced 
pathway of aspirin-treated platelets was not atfected before cardiopulmo- 
nary bypass, but it was impaired more during the operation (p < 0.01) and 
remained worse afterward (p < 0.05), compared with that of placebo- 
treated platelets. The inhibitory etfects of aspirin on thromboxane produc- 
tion and on collagen-induced platelet aggregation remained throughout he 
operation. In aspirin-treated platelets, the aggregation capacity induced by 
adenosine diphosphate was inhibited before the operation (p < 0.05) and 
showed substantial recovery during the operation (p < 0.05). These resuits 
suggest hat the shear-induced pathway of aspirin-treated platelets is more 
vulnerable to cardiopulmonary bypass than the pathway in normal plate- 
lets and causes severe impairment of hemostasis afterward. (J THORAC 
CARDIOVASC SURG 1995;110:813-8) 
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A spirin treatment has become standard for pa- tients who have coronary artery disease. 1 If 
aspirin-treated patients must undergo coronary ar- 
tery bypass grafting (CABG), the concern is the risk 
of increased bleeding during and after the opera- 
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tion. TM Aspirin-treated patients who undergo surgi- 
cal procedures without cardiopulmonary bypass 
(CPB) manifest mild but not profound impairment 
of hemostasis. 5' 6 Moreover, aspirin treatment that is 
begun immediately after CPB is not associated with 
increased bleeding. 7 The hemostatic function of 
aspirin-treated platelets may therefore be more 
vulnerable to CPB than that of normal platelets, 
resulting in more severe impairment of hemostasis 
during and after CPB. 
The hemostatic function of platelets comprises 
two mechanisms: the shear-induced pathway and 
the cyclooxygenase pathway. 8,9 In a recent study, 
we 1° demonstrated that the shear-induced pathway 
of normal platelets is affected by the CPB proce- 
dure. Because the cyclooxygenase pathway is com- 
pletely inhibited in aspirin-treated platelets, their 
hemostatic function mainly depends on the shear- 
induced pathway. Therefore, a double-blind, place- 
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bo-controlled study of preoperative aspirin treat- 
ment (325 mg) was conducted to investigate the 
contribution of the shear-induced pathway to hemo- 
stasis of patients undergoing CABG. 
To measure changes in the shear-induced path- 
way, we introduced the in vitro bleeding test 
(Thrombostat 4000R, VDG-von der Goltz, Seeon, 
Germany). In this test, blood is perfused through a 
capillary (inner diameter 190 um) under constant 
pressure (40 mm Hg) until the shear stress causes a 
platelet hemostatic plug to form on a collagen filter 
at the end of the capillary. 11 The test sensitively 
reflects the function of both platelet adhesion and 
aggregation under shear stress. 12' 13 For comparison, 
the conventional tests for platelets were also per- 
formed: platelet aggregation tests, plasma concen- 
trations of platelet secretory products, and the in 
vivo bleeding test. 
Patients and methods 
Patients. After informed consent was obtained from 
the patients and approval from the institutions review 
board, 40 patients undergoing primary, elective CABG 
entered the randomized, ouble-blind, placebo-controlled 
study. None of the patients was more than 75 years old, 
and none had evidence of severe heart failure, renal or 
hepatic dysfunction, or bleeding diathesis. None of the 
patients was treated with drugs that affect plätelet func- 
tion within 10 days before the operation. None of the 
patients showed abnormal values on the thrombotest 
before the operation. 
Protocol. Forty patients were treated with a study tab- 
let containing aspirin (325 mg) or placebo 10 hours before 
the operation. The study tablets were prepared in the 
pharmacology department of the University Hospital 
Groningen according to a randomized code. The code was 
unknown to all clinicians and investigators until after all 
parameters were obtained. Blood loss was determined 
during and after the operation. Blood samples were taken 
during the operation to test the platelet function. 
Operative techniques. Anesthesia was induced with 
sufentanil (Janssen, Tilburg, The Netherlands) and with 
muscle relaxant, pancuronium bromide (Organon 
Teknika, Boxtel, The Netherlands). Analgesia was contin- 
ued with sufentanil and midazolam (Roche, Mijdrecht, 
The Netherlands). Bovine heparin (300 IU/kg, Leo, Em- 
men, The Netherlands) was administered intravenously 
before cannulation, and additional heparin (100 IU/kg) 
was given every 60 minutes during CPB. A membrane 
oxygenator (COßE Laboratories, Inc., Arvada, Colo.) was 
primed with 2000 ml of oxypolygelatin (Gelifundol, 
Biotest Pharma GmbH, Dreiech, Germany) and 1500 IU 
of bovine heparin. CPB was performed with moderate 
hypothermia (28 ° C nasopharyngeal temperature) with a 
pump flow of 2.4 L/m 2 per minute and a mean arterial 
pressure of 50 to 60 mm Hg. After CPB, heparin was 
neutralized by protamine chloride (3 mg/kg, Hoffmann-La 
Roche BV, Mijdrecht, The Netherlands). The activated 
clotting time was confirmed to be longer than 400 seconds 
during CPB in every patient. 
Blood loss during and after operation. Total hemoglo- 
bin loss during operation was determined by measuring 
the volume and the hemoglobin concentration of the 
content of the suction reservoir and of the rinse water 
after lysis of the red blood cells in all used gauzes. Total 
hemoglobin loss after operation was determined by mea- 
suring the volume and the hemoglobin concentration of
the drainage blood until 12 hours after the operation. This 
content was änticoagulated with 5 ml ethylenediaminetet- 
raacetic acid (0.4 mol/L). 
The in vivo bleeding time. The measurement was per- 
formed before operation by the Ivy method. 
Blood samples. At the induction of anesthesia, 5 min- 
utes after the heparin injection, 5 minutes and 30 minutes 
after the start of CPB, at the end of CPB, and 30 minutes 
after protamine infusion, blood samples were taken from 
the radial arterial ine or the arterial ine of the oxygen- 
ator. Blood samples were collected in 0.38% sodium 
citrate. Indomethacin and diethylcarbamazine (final eon- 
centration of each 50/xg/ml) were immediately added to 
an aliquot for the assays of platelet secretory products. 
Citrated blood was immediately used for the in vitro 
bleeding test and for hematologic measurelnents, and the 
remainder was centrifuged for 15 minutes at 90 g and 
1000 g to obtain platelet-rich plasma and platelet-poor 
plasma, respectively. 
The in vitro bleeding test (Thrombostat). The instru- 
ment (Thrombostat 4000R) and the analysis of the in vitro 
bleeding test (Baxter Diagnosties AG, Dudingen, Switzer- 
land) have been reported in detail. 11-13 The test was 
designed to mimie the primary hemostasis n an injured 
arteriole. In brief, eitrated whole blood was perfused 
through an artificial vessel under constant pressure (40 
mm Hg). This artifieial vessel consists of a Teflon capillary 
(inner diameter 190 /xm, length 20 mm) that ends in a 
eellulose acetate filter aperture (inner diameter 150/xm) 
eovered with collagen type I and soaked with 40 /A of 
adenosine diphosphate (ADP; 10 -2 M). The total in vitro 
bleeding volume was measured until blood flow through 
the capillary was completely stopped by a platelet plug at 
the end of the eapillary. If the bleeding exceeded a total 
volume of 1000 /Xl, the measurement was stopped. The 
measurement was performed in the later half of the 
patients in the study. Eventually, the data were obtained 
in eight patients of eaeh treatment group. 
Laboratory tests. Platelet aggregation i dueed by eol- 
lagen (bovine collagen type I, Sigma Chemieal Company, 
St. Louis, Mo.; final concentration 1/~g/ml) or ADP (final 
eoncentration 2 pM) in platelet-rieh plasma was tested 
with an aggregometer (Payton 300B, Paßon Association 
Ltd., Ontario, Canada). Maximum aggregation was ex- 
pressed as a pereentage of the platelet-rich plasma or 
platelet-poor plasma setting. The plasma concentrations 
of thromboxane B 2 and of/3-thromboglobulin were deter- 
mined by enzyme immunoassay nd by radioimmunoassay 
(Cayman Co., Ann Arbor, Mich., and Amersham Inter- 
national, Ltd., Little Chalfont, Bucks, United Kingdom 
respeetively). Hemoglobin, hematocrit, and platelet num- 
ber were determined with a cell counter (Cell-Dyn 610, 
Sequoia-Turner Corp., Mountain View, Calif.). 
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Table I. Demographic data for the two study groups 
Placebo Aspirin 
(n = 18) (n = 17) 
Age (yr) 58.1 -+ 8.7 60.2 + 7.9 NS 
Body weight (kg) 77.3 -+ 9.7 78.1 _+ 9.5 NS 
CPB time (min) 84.3 + 48.1 87.2 + 22.9 NS 
Number of coronary 2.7 -+ 0.9 2.8 + 1.0 NS 
anastomoses 
All values are mean -+ standard eviation. NS, No statistical significance 
between groups. 
Statistics. The Mann-Whitney U test and the Wilcoxon 
signed rank test were used for comparison of the data 
between groups and within groups, respectively. All data 
were expressed as mean _ standard eviation. Ap value 
less than 0.05 was considered significant. 
Results 
Demographic data showed no significant differ- 
ences between aspirin- and placebo-treated groups 
(Table I). Surgical bleeding was found during retho- 
racotomy in three patients from the aspirin-treated 
group. The protocol could not be followed for 
logistic reasons in two patients from the placebo 
group. These five patients were excluded from the 
subsequent analysis. 
Blood loss. The amount of hemoglobin loss 
tended to be higher in the aspirin-treated group 
than in the placebo-treated group both during and 
after the operation, although the difference was 
significant only after the operation (p < 0.05) (Fig. 
1). 
The in vitro bleeding test (Thrombostat). Before 
CPB, the in vitro bleeding volume was similar in the 
two groups. At 5 minutes after the start of CPB, the 
in vitro bleeding volume had increased substantially 
in both groups (p < 0.01). At 30 minutes after the 
start of CPB, the in vitro bleeding volume had 
further increased, and it was significantly higher in 
the aspirin-treated group than in the placebo- 
treated group (p < 0.01). This significantly higher in 
vitro bleeding volume persisted until the end of 
operation in the aspirin-treated group (p < 0.05) 
(Fig. 2). 
The in vivo bleeding test. The Ivy bleeding time 
before operation was significantly longer in the 
aspirin-treated group than in the placebo-treated 
group (277 _+ 15 versus 197 _ 11 seconds;p < 0.05). 
Platelet aggregation capacity. The aggregation 
capacity induced by ADP was lower before CPB in 
aspirin-treated platelets than in placebo-treated 
platelets! (p < 0.05) but increased in aspirin-treated 
platelets after the onset of CPB (p < 0.05). The 
s 
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Fig. 1. Hemoglobin loss during and after operation. 
Hemoglobin loss was measured uring and after opera- 
tion in the placebo-treated group (white columns, n = 
18), and in the aspirin-treated group (dark columns, n = 
17). *Significant difference between groups (p < 0.05). 
aggregation capacity induced by ADP showed no 
further change during CPB in either group (Fig. 3). 
The aggregation capacity of aspirin-treated platelets 
induced by collagen was consistently ower before 
and at the end of CPB than in the placebo-treated 
platelets (p < 0.05) (Table II). 
Platelet secretory produets. The plasma concen- 
trations of thromboxane B 2 were consistently low in 
the aspirin-treated group, whereas they increased 
significantly during CPB in the placebo-treated 
group (Table III). The plasma concentrations of
/3-thromboglobulin i creased similarly in both 
groups during CPB and reached apeak at the end of 
CPB (Fig. 4). 
Hematologic parameters. The platelet number 
dropped sharply after the start of CPB, and it 
remained approximately 100 × 109/L during and 
after CPB in both groups, with no significant differ- 
ences between the two groups at any point. No 
patients received transfusion of platelet concen- 
trates during the operation. The hematocrit value 
decreased sharply after the start of CPB and re- 
mained constant during and after CPB. There were 
no significant differences in hematocrit values be- 
tween the groups at any point of the study. 
Discussion 
According to the in vitro bleeding test, the shear- 
induced pathway of aspirin-treated platelets was not 
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Fig. 2. The in vitro bleeding test. The in vitro bleeding 
volume through the capillary until the formation of a 
hemostatic plug is indicated against he time course of 
operation i  the placebo-treated group (closed circles, n 
= 8) and in the aspirin-treated group (open squares, n = 
8). Arrow indicates injection of systemic heparin. During 
the first 5 minutes of CPB, the bleeding volume in- 
creased significantly in both groups (p < 0.01). *Signif- 
icant difference between groups (p < 0.05). ** Significant 
differenee between groups (p < 0.01). 
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Fig. 3. Platelet aggregation i duced by ADP. The maxi- 
mum aggregation f aspirin-treated platelets (open squares, 
n = 17) was lower before CPB compared with placebo- 
treated platelets (closed circles, n = 18) (t9 < 0.05) but 
increased after the onset of CPB (p < 0.05) toward the 
aggregation capacity of the placebo-treated platelets. *Sig- 
nificant difference between the groups before operation. 
**Significant difference within the aspirin-treated group 
before operation versus after the start of CPB. 
affected before CPB but became impaired after the 
onset of CPB and remained significantly worse 
during and after CPB eompared with placebo- 
treated platelets. The plasma /3-thromboglobulin 
concentrations increased similarly during CPB in 
both groups. The aggregation capacity of aspirin- 
treated platelets induced by ADP showed an im- 
provement after the start of CPB and became 
similar to the capacity of placebo-treated platelets. 
This result may have been caused by some positive 
synergism 14 between ADP and agonists such as 
thrombin or plasmin that are generated uring 
CPB. 15 Two contrasting phenomena of aspirin- 
treated platelets during CPB, the improvement of 
ADP-induced aggregation and the impairment of 
shear-induced pathway, seem to refiect wo separate 
pathways of platelet aetivation, s Therefore, the im- 
paired hemostasis of the aspirin-treated patients 
after CPB is most likely explained by the impair- 
ment of the shear-induced pathway of aspirin- 
treated platelets during CPB. 
The shear-induced pathway 16' 17 and the cyclooxy- 
genase pathway TM appear to be two major pathways 
of platelet function eontributing to hemostasis and 
thrombosis. 8 The results of this study show that 
aspirin persistently inhibits thromboxane generation 
and collagen-induced platelet aggregation through- 
out the operation. Therefore, the hemostatic func- 
tion of aspirin-treated patients depends mainly on 
the shear-induced pathway. The sequences of the 
shear-indueed pathway of platelet function are the 
binding of plasma von Willebrand factor (vWF) to 
platelet glycoprotein (Gp) Ib, the expression of 
GpIIb/IIIa, and the release of platelet-vWF. 16' 19 
Finally, vWF binds to GpIIb/IIIa, leading to irre- 
versible adhesion)7 An in vitro study 9demonstrated 
that a high shear stress (120 dyne. cm -z) induees 
the immediate release of platelet-vWF multimers 
and the expression of GpIIb/IIIa receptors. In the 
presence of ADP, the released vWF multimers 
immediately bind to platelet reeeptors, 9 which en- 
sures an irreversible platelet adhesion. In a surgical 
wound, shear stress is estimated to be 60 
dyne. cm -2 in an arteriole and higher in a capil- 
lary, 2° vWF multimers are secreted from endothelial 
cells and platelets, 2~ and ADP is generated by eell 
lysis and secretion from platelets. 22 
The in vitro bleeding test generates a shear stress 
of 128 dyne. cm-Z, 11 which is comparable to the 
value estimated in a wound. It is essential to add 
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Table II. Platelet aggregation capacity induced by 
collagen 
Placebo Aspirin 
(n = 18) (n = 17) 
Before CPB 44 _+ 24 8 ± 6 p < 0.05 
At the end of CPB 44 + 23 17 ± 16 p < 0.05 
All values are mean _+ standard eviation. 
Table III. Plasma thromboxane B e concentration 
Placebo Aspirin 
(n = 18) (n = 17) 
Before CPB 32.0 ± 16.4 15.4 _+ 9.6 p < 0.05 
During CPB 
After 5 minutes 96.9 + 54.9 21.8 _+ 8.9 p < 0.01 
After 30 minutes 99.8 +- 64.1 20.8 ± 10.0 p < 0.01 
After CPB 86.0 _+ 62.2 12.8 -4- 5.0 p < 0.01 
All values are mean -+ standard eviation. Thromboxane B 2 concentra- 
tions are picograms per milliliter. 
ADP on the filter, because abnormally prolonged 
test values have been obtained after aspirin treat- 
ment in the absence of ADP. a3 The binding of 
released platelet-vWF induced by ADP seems to 
play a dominant role in platelet plug formation at 
this specific shear rate in the in vitro bleeding test, 9
and this activation pathway is not affected by aspi- 
rin.8, 9 Because alterations in the clotting system, 23 
in the cyclooxygenase pathway, 24 and in the skin 
temperature 2s can affect the conventional in vivo 
bleeding test, the in vitro bleeding test is more 
specific to monitor the shear-induced pathway of 
platelet function. 
The effects of CPB on the shear-induced pathway 
in normal p•atelets and in aspirin-treated platelets 
were clearly shown in this study. The abrupt increase 
in the in vitro bleeding volume in both groups after 
the start of CPB reflects mainly an altered hemo- 
static function of platelets and partly a hemodilu- 
tion. a° The significant differences in the in vitro 
bleeding volume between the two groups indicate 
that the hemostatic function of the aspirin-treated 
platelets was more affected uring CPB. The effect 
of CPB on normal platelets has been described as 
the loss of platelet reaetivity 26and as the impair- 
ment of platelet membrane receptors GpIb 27' 28 or 
GpIIb/IIIa. 29 Consequently, sensitivity to change in 
platelet shape is diminished uring CPB, according 
to the morphologic study of Zilla and associates. 3° 
Although the vulnerability of aspirin-treated plate- 
lets to CpB has not been documented previously, 
the typical behavior of aspirin-treated platelets dem- 
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Fig. 4. Plasma 13-thromboglobulin ([3-TG) concentra- 
tion. The plasma concentration f/3-thromboglobulin is 
indicated, during the operation in the placebo-treated 
group (closed circles, n = 18) and in the aspirin-treated 
group (open squares, n = 17). 
onstrated in this study has also been shown in recent 
in vitro studies. 22' 31 Those reports described the 
platelet-vWF release as subtotally dependent on 
shape change in aspirin-treated platelets, whereas it 
is independent in normal platelets. Our in vitro 
bleeding test clearly demonstrated that the hemo- 
static function of aspirin-treated platelets was im- 
paired during the initial 30 minutes of CPB, exactly 
when platelets lose the sensitivity to shape change, 
according to the observation of Zilla's group. 3° 
Therefore, the platelet-vWF release is a crucial step 
in the shear-induced platelets because of the defect 
in platelet shape change acquired uring CPB. This 
could result in severe impairment of hemostasis 
during and after CPB in aspirin-treated patients. 
Aspirin and placebo tablets were supplied by Bayer AG, 
Leverkusen, Germany. We sincerely appreciate the gen- 
erous help from members of the Thorax Center of Gron- 
ingen University Hospital. 
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